Sweden-Based Cyxone, A Developer Of Therapies For Diseases Such As Rheumatoid Arthritis And Multiple Sclerosis As Well As Treatments For Virally Induced Acute Respiratory Disorders, Has Engaged A Major European Contract Development And Manufacturing Organization ( Cdmo ) For The Scale-Up And Production Of The Active Ingredient Of Its Drug Candidate T20K. The Production Will Be Performed In Accordance With Good Manufacturing Practice ( Gmp ), Exploring A Brand-New Manufacturing Method. The Collaboration Will Initially Cover Method Development And Later Supply Material For Use In Non-Clinical And Clinical Development Activities.Cyxone Is Developing T20K, A Peptide Aimed For The Treatment Of Multiple Sclerosis (Ms). Preclinical Data Indicate That The Drug Candidate Prevents Disease Progression In A Model System And Therefore Shows Potential To Slow Or Prevent Disease Progression Including Preventing The Demyelination Which Causes The Symptoms Of Ms.
